• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.

作者信息

Molica Matteo, Canichella Martina, Alunni Fegatelli Danilo, Colafigli Gioia, Massaro Fulvio, Latagliata Roberto, Foà Robin, Breccia Massimo

机构信息

Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

出版信息

Am J Hematol. 2017 Dec;92(12):E661-E664. doi: 10.1002/ajh.24913. Epub 2017 Oct 19.

DOI:10.1002/ajh.24913
PMID:28940255
Abstract
摘要

相似文献

1
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.Eutos长期生存评分能准确预测在临床试验之外接受治疗的慢性髓性白血病患者的死亡风险。
Am J Hematol. 2017 Dec;92(12):E661-E664. doi: 10.1002/ajh.24913. Epub 2017 Oct 19.
2
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents.基于儿童和青少年慢性髓性白血病国际登记处的 EUTOS 长期生存评分的预后判别。
Haematologica. 2017 Oct;102(10):1704-1708. doi: 10.3324/haematol.2017.170035. Epub 2017 Aug 24.
3
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.EUTOS 评分可预测慢性髓性白血病患者的长期预后，但不能预测伊马替尼的最佳反应。
Leuk Res. 2013 Nov;37(11):1457-60. doi: 10.1016/j.leukres.2013.07.037. Epub 2013 Aug 11.
4
Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline.基线时p210和p190共表达的慢性髓性白血病患者的长期预后
Br J Haematol. 2015 Apr;169(1):148-50. doi: 10.1111/bjh.13184. Epub 2014 Oct 9.
5
The pros and cons of new prognostic eutos score for chronic myeloid leukemia patients.慢性髓系白血病患者新预后欧洲白血病网络（ELN）评分的利弊
Leuk Res. 2013 Nov;37(11):1436-7. doi: 10.1016/j.leukres.2013.08.013. Epub 2013 Sep 5.
6
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia.异基因干细胞移植前使用去甲基化药物治疗可改善慢性粒单核细胞白血病患者的无进展生存期。
Biol Blood Marrow Transplant. 2016 Jan;22(1):47-53. doi: 10.1016/j.bbmt.2015.08.031. Epub 2015 Sep 4.
7
[Chronic myeloid leukemia: a decade of progress].[慢性髓性白血病：十年进展]
Med Clin (Barc). 1990 Jan 13;94(1):27-35.
8
Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.大剂量伊马替尼治疗儿童和青少年慢性期慢性髓性白血病的长期结果：意大利的经验。
Br J Haematol. 2015 Aug;170(3):398-407. doi: 10.1111/bjh.13453. Epub 2015 Apr 20.
9
Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.早期干细胞移植在慢性髓系白血病中起作用吗？反对该提议。
Lancet Oncol. 2005 Sep;6(9):722-3.
10
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.EUTOS评分可识别出接受伊马替尼一线或二线治疗、预后较差的慢性髓性白血病患者。
Leuk Res. 2012 Sep;36(9):e209-10. doi: 10.1016/j.leukres.2012.05.011. Epub 2012 Jul 6.

引用本文的文献

1
Prognostic scoring systems in chronic myeloid leukaemia.慢性髓性白血病的预后评分系统
Leukemia. 2025 May;39(5):1046-1052. doi: 10.1038/s41375-025-02606-6. Epub 2025 Apr 15.
2
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.二代酪氨酸激酶抑制剂作为一线治疗药物引入后慢性髓性白血病治疗方式和结局的变化：CML 合作研究组的一项多机构回顾性研究。
Int J Hematol. 2024 Jul;120(1):60-70. doi: 10.1007/s12185-024-03758-4. Epub 2024 Apr 8.
3
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.
慢性髓性白血病的预后：基线因素、动态风险评估和新的见解。
Cells. 2023 Jun 23;12(13):1703. doi: 10.3390/cells12131703.
4
A Retrospective Cohort Study of Upfront Nilotinib in Chronic Myeloid Leukemia: A Single-Center Experience.一项关于一线尼罗替尼治疗慢性髓性白血病的回顾性队列研究：单中心经验
South Asian J Cancer. 2021 Nov 24;10(4):246-250. doi: 10.1055/s-0041-1733301. eCollection 2021 Dec.
5
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.慢性髓性白血病患者总生存的预后因素：意大利慢性髓性白血病GIMEMA网络的一项多中心队列研究
Front Oncol. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. eCollection 2021.
6
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.EUTOS 长期生存评分可预测基于实践队列的慢性髓系白血病患者的疾病特异性死亡率和分子反应。
Cancer Med. 2020 Dec;9(23):8931-8939. doi: 10.1002/cam4.3516. Epub 2020 Oct 10.
7
Validation of the EUTOS Long-Term Survival Score in Chinese Chronic Myeloid Leukemia Patients Treated with Imatinib: A Multicenter Real-World Study.伊马替尼治疗的中国慢性髓性白血病患者中EUTOS长期生存评分的验证：一项多中心真实世界研究
Cancer Manag Res. 2020 Feb 20;12:1293-1301. doi: 10.2147/CMAR.S237467. eCollection 2020.
8
Early Management of CML.慢性髓性白血病的早期治疗。
Curr Hematol Malig Rep. 2019 Dec;14(6):480-491. doi: 10.1007/s11899-019-00550-8.